Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy
暂无分享,去创建一个
Jingyao Chen | Z. Zeng | Xuan Li | Jian He | Wenhan Huang | S. Fan | Xiaohong Xu | Qi Zhang
[1] Haiyong Wang,et al. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy , 2022, Clinical and Translational Oncology.
[2] Shulan Sun,et al. Predictive value of NLR and PLR in response to preoperative chemotherapy and prognosis in locally advanced gastric cancer , 2022, Frontiers in Oncology.
[3] P. Lequerica-Fernández,et al. Prognostic implications of preoperative systemic inflammatory markers in oral squamous cell carcinoma, and correlations with the local immune tumor microenvironment , 2022, Frontiers in Immunology.
[4] Huifang Liang,et al. Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives , 2022, Frontiers of Medicine.
[5] M. Mego,et al. Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers , 2022, Journal of clinical medicine.
[6] K. Sartorius,et al. Emerging Perspectives of Bone Metastasis in Hepatocellular Carcinoma , 2022, Frontiers in Oncology.
[7] J. Menten,et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. , 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] T. Rygiel,et al. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options , 2022, International journal of molecular sciences.
[9] J. Arnoletti,et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation , 2022, PloS one.
[10] M. Braga,et al. Association Between Systemic Inflammation and Malnutrition With Survival in Patients With Cancer Sarcopenia—A Prospective Multicenter Study , 2022, Frontiers in Nutrition.
[11] Jing Chen,et al. Preoperative Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Predict Survival Outcomes of Patients With Hepatocellular Carcinoma After Curative Resection , 2022, Frontiers in Oncology.
[12] Liaoliao Dong,et al. Neutrophils in cancer carcinogenesis and metastasis , 2021, Journal of Hematology & Oncology.
[13] Hong Chang,et al. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram , 2021, Scientific Reports.
[14] K. Dou,et al. Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection , 2021, Cancer Cell International.
[15] Xutong Li,et al. Prognostic significance of inflammation-based score in patients with hepatocellular carcinoma after liver transplantation , 2021, European journal of gastroenterology & hepatology.
[16] Peng Du,et al. Diagnostic Value of Inflammatory Factors in Pathology of Bladder Cancer Patients , 2020, Frontiers in Molecular Biosciences.
[17] M. Cho,et al. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma , 2020, BMC cancer.
[18] Chengliang Zhao,et al. Diagnostic and prognostic nomograms for bone metastasis in hepatocellular carcinoma , 2020, BMC Cancer.
[19] Hongyu Wang,et al. Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization , 2020, Cancer management and research.
[20] Y. Huang,et al. Prognostic impact of elevated pre-treatment systemic immune-inflammation index (SII) in hepatocellular carcinoma , 2020, Medicine.
[21] Xiao-mei Zhao,et al. Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy , 2019, Cancer management and research.
[22] M. Lotze,et al. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer , 2019, Annals of Surgical Oncology.
[23] Li Ma,et al. A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR , 2019, BMC Cancer.
[24] Tingting Li,et al. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma , 2019, BMC Cancer.
[25] I. B. Manuaba,et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer , 2019, Asian Pacific journal of cancer prevention : APJCP.
[26] M. Schlesinger. Role of platelets and platelet receptors in cancer metastasis , 2018, Journal of Hematology & Oncology.
[27] P. Galle,et al. Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma , 2018, Liver Cancer.
[28] A. Singal,et al. Stereotactic ablative radiotherapy for hepatocellular carcinoma: History, current status, and opportunities , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[29] Qiong Yang,et al. Clinical baseline and prognostic difference of platelet lymphocyte ratio (PLR) in right-sided and let-sided colon cancers , 2017, BMC Cancer.
[30] W. Jochum,et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.
[31] K. E. Visser,et al. Neutrophils in cancer: neutral no more , 2016, Nature Reviews Cancer.
[32] Yao Liang,et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) , 2016, BMC Cancer.
[33] S. Shen,et al. A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection: the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) , 2016, BMC Cancer.
[34] Y. Huang,et al. A randomized trial of conventional fraction versus hypofraction radiotherapy for bone metastases from hepatocellular carcinoma , 2015, Journal of Cancer.
[35] S. Clarke,et al. Cancer-related inflammation and treatment effectiveness. , 2014, The Lancet. Oncology.
[36] T. Fehm,et al. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. , 2013, Anticancer Research.
[37] G. Opdenakker,et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. , 2012, Blood.
[38] T. Goto,et al. Hepatocellular carcinoma with extrahepatic metastasis , 2011, Cancer.
[39] Ping Yang,et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy , 2009, Cancer.
[40] F. Schmidt. Meta-Analysis , 2008 .
[41] Sirong Chen,et al. Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma , 2007, Journal of Nuclear Medicine.
[42] T. Kuzuya,et al. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000 , 2004, Cancer.
[43] Qiang Zhao,et al. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer. , 2022, American journal of translational research.
[44] N. Kemeny,et al. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[45] P. Kupelian,et al. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. , 2016, Clinical lung cancer.
[46] Y. Maehara,et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. , 2013, Journal of hepatology.